We believe in
overcoming problems
by going into the
first principles
of science.
We believe in overcoming problems by going into the first principles of science.
Rubicon Research has 2 state-of-the-art R&D centers in India and Canada.
Our R&D Centers
As of March 31, 2024, we operate R&D centers in Thane, Maharashtra, India and Ontario, Canada. Our DSIR approved R&D center in Thane, Maharashtra, India is spread over approximately 38,000 square feet and has three separate laboratories for general, sterile, and potent compounds. It was inspected by the US FDA in June 2023 pursuant to which we received the EIR in June 2024.
Our R&D center in Ontario, Canada is housed in a 13,609.69 square feet facility with laboratories built to cGMP standards and analytical and characterization capabilities for nasal and inhalation products. It was inspected by the US FDA in July 2016, October 2018, and most recently in November 2023 pursuant to which we received an EIR in December 2023.
The table below provides details of our R&D centers, as of March 31, 2024:
| Location | Segment | Description |
|---|---|---|
| Thane, Maharashtra, India |
Multi-segment | R&D centers for formulations across various dosage forms, including oral solids, oral liquids, injectables, ophthalmic, and topicals. |
| Ontario, Canada | Nasal & inhalation | R&D centers for formulation of nasal and inhalation products such as nasal sprays, dry powder inhalers, metered dose inhalers, etc. |